

BIONICAL SOLUTIONS LIMITED

**Company Registration Number:
04313379 (England and Wales)**

Unaudited statutory accounts for the year ended 31 December 2020

Period of accounts

Start date: 1 January 2020

End date: 31 December 2020

BIONICAL SOLUTIONS LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2020

Directors report

Profit and loss

Balance sheet

Additional notes

Balance sheet notes

BIONICAL SOLUTIONS LIMITED

Directors' report period ended 31 December 2020

The directors present their report with the financial statements of the company for the period ended 31 December 2020

Principal activities of the company

provision of healthcare services

Political and charitable donations

nil

Directors

The directors shown below have held office during the whole of the period from
1 January 2020 to 31 December 2020

AT Borkowski
G Davies
H Miles

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
19 April 2021

And signed on behalf of the board by:

Name: AT Borkowski
Status: Director

BIONICAL SOLUTIONS LIMITED

Profit And Loss Account for the Period Ended 31 December 2020

	2020	2019
	£	£
Turnover:	22,009,000	8,665,000
Cost of sales:	(14,982,000)	(4,827,000)
Gross profit(or loss):	7,027,000	3,838,000
Administrative expenses:	(4,344,000)	(4,345,000)
Operating profit(or loss):	2,683,000	(507,000)
Interest payable and similar charges:	(455,000)	(363,000)
Profit(or loss) before tax:	2,228,000	(870,000)
Tax:	(238,000)	54,000
Profit(or loss) for the financial year:	1,990,000	(816,000)

BIONICAL SOLUTIONS LIMITED

Balance sheet

As at 31 December 2020

	<i>Notes</i>	<i>2020</i>	<i>2019</i>
		£	£
Fixed assets			
Intangible assets:	3	33,000	81,000
Tangible assets:	4	635,000	282,000
Total fixed assets:		<u>668,000</u>	<u>363,000</u>
Current assets			
Debtors:	5	11,072,000	3,120,000
Cash at bank and in hand:		931,000	119,000
Total current assets:		<u>12,003,000</u>	<u>3,239,000</u>
Creditors: amounts falling due within one year:	6	(10,085,000)	(3,991,000)
Net current assets (liabilities):		<u>1,918,000</u>	<u>(752,000)</u>
Total assets less current liabilities:		<u>2,586,000</u>	<u>(389,000)</u>
Creditors: amounts falling due after more than one year:	7	(950,000)	
Provision for liabilities:		(72,000)	(37,000)
Total net assets (liabilities):		<u>1,564,000</u>	<u>(426,000)</u>
Capital and reserves			
Called up share capital:		1,000	1,000
Profit and loss account:		1,563,000	(427,000)
Total Shareholders' funds:		<u>1,564,000</u>	<u>(426,000)</u>

The notes form part of these financial statements

BIONICAL SOLUTIONS LIMITED

Balance sheet statements

For the year ending 31 December 2020 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

**This report was approved by the board of directors on 19 April 2021
and signed on behalf of the board by:**

Name: AT Borkowski
Status: Director

The notes form part of these financial statements

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

1. Accounting policies

Basis of measurement and preparation

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

Turnover policy

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets depreciation policy

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses. The company assesses at each reporting date whether tangible fixed assets are impaired. Depreciation is charged to the profit and loss account on a straight-line basis over the estimated useful lives of each part of an item of tangible fixed assets. Leased assets are depreciated over the shorter of the lease term and their useful lives. Land is not depreciated. The estimated useful lives are as followsShort-term leasehold property 10 yearsPlant, machinery, fixtures & fittings 3 - 5 yearsDepreciation methods, useful lives and residual values are reviewed if there is an indication of a significant change since last annual reporting date in the pattern by which the company expects to consume an asset's future economic benefits.

Intangible fixed assets amortisation policy

Expenditure on internally generated goodwill and brands is recognised in the profit and loss account as an expense as incurred.Other intangible assets that are acquired by the Company are stated at cost less accumulated amortisation and less accumulated impairment losses.

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2020

2. Employees

	<i>2020</i>	<i>2019</i>
Average number of employees during the period	368	153

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

3. Intangible assets

	Goodwill	Other	Total
Cost	£	£	£
At 1 January 2020		177,000	177,000
Additions			
Disposals			
Revaluations			
Transfers			
At 31 December 2020		177,000	177,000
Amortisation			
At 1 January 2020		96,000	96,000
Charge for year		48,000	48,000
On disposals			
Other adjustments			
At 31 December 2020		144,000	144,000
Net book value			
At 31 December 2020		33,000	33,000
At 31 December 2019		81,000	81,000

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

4. Tangible assets

	Land & buildings	Plant & machinery	Fixtures & fittings	Office equipment	Motor vehicles	Total
Cost	£	£	£	£	£	£
At 1 January 2020		778,000				778,000
Additions		560,000				560,000
Disposals						
Revaluations						
Transfers						
At 31 December 2020		1,338,000				1,338,000
Depreciation						
At 1 January 2020		496,000				496,000
Charge for year		207,000				207,000
On disposals						
Other adjustments						
At 31 December 2020		703,000				703,000
Net book value						
At 31 December 2020		635,000				635,000
At 31 December 2019		282,000				282,000

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2020

5. Debtors

	<i>2020</i>	<i>2019</i>
	£	£
Trade debtors	7,313,000	1,683,000
Prepayments and accrued income	2,654,000	410,000
Other debtors	1,105,000	1,027,000
Total	<u>11,072,000</u>	<u>3,120,000</u>

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

6. Creditors: amounts falling due within one year note

	<i>2020</i>	<i>2019</i>
	£	£
Trade creditors	1,660,000	220,000
Taxation and social security	1,462,000	235,000
Accruals and deferred income	1,027,000	861,000
Other creditors	5,936,000	2,675,000
Total	<u>10,085,000</u>	<u>3,991,000</u>

BIONICAL SOLUTIONS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2020

7. Creditors: amounts falling due after more than one year note

	<i>2020</i>
	£
Other creditors	950,000
Total	<u>950,000</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.